Octava Pink
Commercial- Indications
- Breast cancer
Company intelligence / Profile preview
Eventus Diagnostics
Miami, Florida, United Statesprnewswire.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Eventus Diagnostics has developed the Octava blood test, an immune-based diagnostic intended for early breast cancer detection. The company completed a $2.72 million financing round to support commercialization efforts. Clinical results or regulatory status are not detailed in public sources but the company was preparing for market entry as of 2014[5].
- Therapeutic areas
- Oncology
- Modalities
- Device (blood test)In vitro diagnostic assayImmune-based diagnostic technology
- Industry
- Protein Biomarker Diagnostics
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →Beyond the preview
Go deeper on Eventus Diagnostics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Eventus Diagnostics.